Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
Yazar:: Erola Ainsua-Enrich, Núria Pedreño-Lopez, Carmen Bracke, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Edwards Pradenas, Benjamin Trinité, Silvia Marfil, Cristina Miranda, Sandra González, Ruth Toledo, Marta Font, Susana Benet, Tuixent Escribà, Esther Jimenez-Moyano, Ruth Peña, Samandhy Cedeño, Julia G. Prado, Beatriz Mothe, Christian Brander, Nuria Izquierdo-Useros, Julia Vergara-Alert, Joaquim Segalés, Marta Massanella, Rosa María Benitez, Alba Romero, Daniel Molina-Morant, Julià Blanco, Bonaventura Clotet, Lourdes Mateu, María Luisa Pedro-Botet, Jorge Carrillo
| Materyal Türü: | Article |
|---|---|
| Baskı/Yayın Bilgisi: | Elsevier 2022-11-01 |
Diğer Bilgiler
Summary: Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.